GlassScriptPhysician profile
Kacey A Tomko
NPI 1104122233
$5,674.87
in general payments reported to CMS, 2019-2025
26 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $784 · 2022: $1,223 · 2023: $1,449 · 2024: $1,054 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,593 · Education: $75.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,592.57 |
| Education | $75.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $772.51 | 2021-2025 | Caplyta |
| Abbvie INC. | $632.90 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $611.58 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $606.96 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $463.96 | 2021-2025 | Rexulti |
| Alkermes, INC. | $431.32 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $355.63 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $291.12 | 2024-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $216.30 | 2021-2024 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $180.67 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $177.02 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $145.91 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $127.46 | 2021-2025 | Trintellix |
| Eisai INC. | $126.47 | 2021-2024 | |
| Novo Nordisk INC | $99.95 | 2023-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $88.76 | 2021-2023 | Belsomra |
| Indivior INC. | $55.61 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $49.77 | 2022-2024 | Nuplazid |
| Almatica Pharma LLC | $48.30 | 2025 | Loreev Xr |
| Neos Therapeutics, LP | $43.42 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $35.31 | 2021 | |
| Corium, LLC | $34.44 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $27.56 | 2022-2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $17.47 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.44 | 2023 | Quviviq |
| Biogen, INC. | $17.03 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacey Tomko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.